 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for developing evidence-based guidance for the National Health Service
on whether new medicines represent a clinically and cost-effective use of resources.
NICE published guidance in August 2022 recommending both ceftazidime with avibactam
and cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
This was as part of a project to test a new health technology evaluation process and
payment model for antimicrobial products. NHS England has now issued contracts with
the suppliers and cefiderocol and ceftazidime with avibactamare available for clinicians
to prescribe in line with NICE’s recommendations.</p>
|
 |
